{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:27:36Z","timestamp":1793662056109,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:00:00Z","timestamp":1793664000000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Stichting Maastricht Radiation Oncology \u2013 Maastro","award":["No specific grant number"],"award-info":[{"award-number":["No specific grant number"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01598-5","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:53:19Z","timestamp":1783633999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6812-2897","authenticated-orcid":false,"given":"Rianne D. W.","family":"Vaes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E. W. G.","family":"Laven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowen","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa T. J.","family":"Welbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda A. F.","family":"Piepers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Hillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Clarijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Decaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Montaudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus J.","family":"Blok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy T. M.","family":"Sprooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiye","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G.","family":"Maessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette H. R. J.","family":"Degens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel H. M.","family":"Gronenschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L. J.","family":"Custers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik R.","family":"de Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik C.","family":"van Gent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Vooijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1598_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino, M. C. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J. Clin. Oncol. 41, 1992\u20131998 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1598_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello, S. et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J. Clin. Oncol. 41, 1999\u20132006 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1598_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. J. Clin. Oncol. 40, 1301\u20131311 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1598_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1598_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans, A. C. et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606). Ann. Oncol. 32, 839\u2013853 (2021).","journal-title":"Ann. Oncol."},{"key":"1598_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358\u2013376 (2023).","journal-title":"Ann. Oncol."},{"key":"1598_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339\u2013357 (2023).","journal-title":"Ann. Oncol."},{"key":"1598_CR9","doi-asserted-by":"publisher","unstructured":"Zer, A. et al. Early and locally advanced non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.003 (2025).","DOI":"10.1016\/j.annonc.2025.08.003"},{"key":"1598_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103050","volume":"143","author":"SP Patel","year":"2026","unstructured":"Patel, S. P., Gadgeel, S., Mino-Kenudson, M., Naidoo, J. & Sethakorn, N. Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. Cancer Treat. Rev. 143, 103050 (2026).","journal-title":"Cancer Treat. Rev."},{"key":"1598_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00168-1","volume":"5","author":"GE Wensink","year":"2021","unstructured":"Wensink, G. E. et al. Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. npj Precis. Oncol. 5, 30 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1598_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00865-1","volume":"9","author":"BP Gladstone","year":"2025","unstructured":"Gladstone, B. P. et al. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. npj Precis. Oncol. 9, 96 (2025).","journal-title":"npj Precis. Oncol."},{"key":"1598_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.641980","volume":"11","author":"M Verduin","year":"2021","unstructured":"Verduin, M., Hoeben, A., De Ruysscher, D. & Vooijs, M. Patient-derived cancer organoids as predictors of treatment response. Front. Oncol. 11, 641980 (2021).","journal-title":"Front. Oncol."},{"key":"1598_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","volume":"20","author":"AWJ van Renterghem","year":"2023","unstructured":"van Renterghem, A. W. J., van de Haar, J. & Voest, E. E. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nat. Rev. Clin. Oncol. 20, 305\u2013317 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1598_CR15","doi-asserted-by":"publisher","unstructured":"Gerke, S., Balamut, J. & Wagner, J. K. The FDA\u2019s plan to phase out animal testing. Trends Biotechnol. https:\/\/doi.org\/10.1016\/j.tibtech.2025.12.011 (2026).","DOI":"10.1016\/j.tibtech.2025.12.011"},{"key":"1598_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107533","volume":"190","author":"JA Taverna","year":"2024","unstructured":"Taverna, J. A. et al. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine. Lung Cancer 190, 107533 (2024).","journal-title":"Lung Cancer"},{"key":"1598_CR17","doi-asserted-by":"publisher","unstructured":"Zipprick, J. et al. Ex-vivo drug-sensitivity testing to predict clinical response in non-small cell lung cancer and pleural mesothelioma: a systematic review and narrative synthesis. Cancers 17. https:\/\/doi.org\/10.3390\/cancers17060986 (2025).","DOI":"10.3390\/cancers17060986"},{"key":"1598_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107588","volume":"31","author":"KK Dijkstra","year":"2020","unstructured":"Dijkstra, K. K. et al. Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine. Cell Rep. 31, 107588 (2020).","journal-title":"Cell Rep."},{"key":"1598_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101777","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu, Y. et al. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Rep. Med. 5, 101777 (2024).","journal-title":"Cell Rep. Med."},{"key":"1598_CR20","doi-asserted-by":"publisher","unstructured":"Sachs, N. et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 38, https:\/\/doi.org\/10.15252\/embj.2018100300 (2019).","DOI":"10.15252\/embj.2018100300"},{"key":"1598_CR21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-19-1376","volume":"26","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin. Cancer Res. 26, 1162\u20131174 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1598_CR22","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/1759-7714.13542","volume":"11","author":"JH Chen","year":"2020","unstructured":"Chen, J. H. et al. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Thorac. Cancer 11, 2279\u20132290 (2020).","journal-title":"Thorac. Cancer"},{"key":"1598_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11867-6","volume":"10","author":"M Kim","year":"2019","unstructured":"Kim, M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat. Commun. 10, 3991 (2019).","journal-title":"Nat. Commun."},{"key":"1598_CR24","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1158\/1078-0432.CCR-20-5026","volume":"27","author":"SY Kim","year":"2021","unstructured":"Kim, S. Y. et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin. Cancer Res. 27, 4397\u20134409 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1598_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101411","volume":"23","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Human lung adenocarcinoma-derived organoid models for drug screening. iScience 23, 101411 (2020).","journal-title":"iScience"},{"key":"1598_CR26","doi-asserted-by":"publisher","unstructured":"Takahashi, N. et al. An in vitro system for evaluating molecular targeted drugs using lung patient-derived tumor organoids. Cells 8, https:\/\/doi.org\/10.3390\/cells8050481 (2019).","DOI":"10.3390\/cells8050481"},{"key":"1598_CR27","first-page":"635","volume":"40","author":"H Tamura","year":"2018","unstructured":"Tamura, H. et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncol. Rep. 40, 635\u2013646 (2018).","journal-title":"Oncol. Rep."},{"key":"1598_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers, H. Modeling development and disease with organoids. Cell 165, 1586\u20131597 (2016).","journal-title":"Cell"},{"key":"1598_CR29","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","volume":"378","author":"JP van Meerbeeck","year":"2011","unstructured":"van Meerbeeck, J. P., Fennell, D. A. & De Ruysscher, D. K. Small-cell lung cancer. Lancet 378, 1741\u20131755 (2011).","journal-title":"Lancet"},{"key":"1598_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"1598_CR31","doi-asserted-by":"publisher","unstructured":"Decaudin, D. et al. Evaluation of combined chemotherapy and genomic-driven targeted therapy in patient-derived xenografts identifies new therapeutic approaches in squamous non-small-cell lung cancer patients. Cancers 16, https:\/\/doi.org\/10.3390\/cancers16162785 (2024).","DOI":"10.3390\/cancers16162785"},{"key":"1598_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis, F. & Heymach, J. V. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat. Rev. Cancer 19, 495\u2013509 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1598_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22676-1","volume":"12","author":"Y Hu","year":"2021","unstructured":"Hu, Y. et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat. Commun. 12, 2581 (2021).","journal-title":"Nat. Commun."},{"key":"1598_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1309\/AJCPEGZMJKC42VUP","volume":"139","author":"RL Schmidt","year":"2013","unstructured":"Schmidt, R. L., Witt, B. L., Lopez-Calderon, L. E. & Layfield, L. J. The influence of rapid onsite evaluation on the adequacy rate of fine-needle aspiration cytology: a systematic review and meta-analysis. Am. J. Clin. Pathol. 139, 300\u2013308 (2013).","journal-title":"Am. J. Clin. Pathol."},{"key":"1598_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03890-7","volume":"12","author":"Z Deng","year":"2021","unstructured":"Deng, Z., Wang, H., Liu, J., Deng, Y. & Zhang, N. Comprehensive understanding of anchorage-independent survival and its implication in cancer metastasis. Cell Death Dis. 12, 629 (2021).","journal-title":"Cell Death Dis."},{"key":"1598_CR36","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/onc.2009.139","volume":"28","author":"S Mori","year":"2009","unstructured":"Mori, S. et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28, 2796\u20132805 (2009).","journal-title":"Oncogene"},{"key":"1598_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-0530-4","volume":"18","author":"R Baghban","year":"2020","unstructured":"Baghban, R. et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 18, 59 (2020).","journal-title":"Cell Commun. Signal."},{"key":"1598_CR38","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0003","volume":"3","author":"TG Meijer","year":"2017","unstructured":"Meijer, T. G., Naipal, K. A., Jager, A. & van Gent, D. C. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci. OA 3, FSO190 (2017).","journal-title":"Future Sci. OA"},{"key":"1598_CR39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586\u20131598.e1512 (2018).","journal-title":"Cell"},{"key":"1598_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41586-024-07791-5","volume":"633","author":"T Recaldin","year":"2024","unstructured":"Recaldin, T. et al. Human organoids with an autologous tissue-resident immune compartment. Nature 633, 165\u2013173 (2024).","journal-title":"Nature"},{"key":"1598_CR41","volume":"89","author":"P Lajoinie","year":"2026","unstructured":"Lajoinie, P. et al. Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression. Respir. Med. Res. 89, 101253 (2026).","journal-title":"Respir. Med. Res."},{"key":"1598_CR42","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard, D. et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N. Engl. J. Med. 389, 1935\u20131948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1598_CR43","unstructured":"FDA. Roadmap to Reducing Animal Testing in Preclinical Safety Studies (FDA, 2025)."},{"key":"1598_CR44","first-page":"114","volume":"6","author":"IW Mak","year":"2014","unstructured":"Mak, I. W., Evaniew, N. & Ghert, M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114\u2013118 (2014).","journal-title":"Am. J. Transl. Res."},{"key":"1598_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/02611929231157756","volume":"51","author":"LJ Marshall","year":"2023","unstructured":"Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K. & Pistollato, F. Poor translatability of biomedical research using animals - a narrative review. Alter. Lab. Anim. 51, 102\u2013135 (2023).","journal-title":"Alter. Lab. Anim."},{"key":"1598_CR46","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. J. Am. Med. Assoc. 333, 71\u201374 (2025).","DOI":"10.1001\/jama.2024.21972"},{"key":"1598_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2016.05.012","volume":"19","author":"H Mou","year":"2016","unstructured":"Mou, H. et al. Dual SMAD signaling inhibition enables long-term expansion of diverse epithelial basal cells. Cell Stem Cell 19, 217\u2013231 (2016).","journal-title":"Cell Stem Cell"},{"key":"1598_CR48","doi-asserted-by":"publisher","unstructured":"Seoane, J. & Gomis, R. R. TGF-beta family signaling in tumor suppression and cancer progression. Cold Spring Harb Perspect. Biol. 9, https:\/\/doi.org\/10.1101\/cshperspect.a022277 (2017).","DOI":"10.1101\/cshperspect.a022277"},{"key":"1598_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.anndiagpath.2012.07.006","volume":"17","author":"MJ Kim","year":"2013","unstructured":"Kim, M. J., Shin, H. C., Shin, K. C. & Ro, J. Y. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Ann. Diagn. Pathol. 17, 85\u201390 (2013).","journal-title":"Ann. Diagn. Pathol."},{"key":"1598_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06785-6","volume":"20","author":"EMP Steeghs","year":"2020","unstructured":"Steeghs, E. M. P. et al. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. BMC Cancer 20, 291 (2020).","journal-title":"BMC Cancer"},{"key":"1598_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2119-2","volume":"16","author":"KA Naipal","year":"2016","unstructured":"Naipal, K. A. et al. Tumor slice culture system to assess drug response of primary breast cancer. BMC Cancer 16, 78 (2016).","journal-title":"BMC Cancer"},{"key":"1598_CR52","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1598_CR53","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-09-3066","volume":"16","author":"F Nemati","year":"2010","unstructured":"Nemati, F. et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and\/or metastatic tumors. Clin. Cancer Res. 16, 2352\u20132362 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1598_CR54","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00595-017-1594-7","volume":"48","author":"M Inoue","year":"2018","unstructured":"Inoue, M. et al. Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer. Surg. Today 48, 380\u2013387 (2018).","journal-title":"Surg. Today"},{"key":"1598_CR55","doi-asserted-by":"publisher","unstructured":"Papp, E. et al. Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas. BMJ Open Respir Res. 7, https:\/\/doi.org\/10.1136\/bmjresp-2019-000505 (2020)","DOI":"10.1136\/bmjresp-2019-000505"},{"key":"1598_CR56","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4149\/neo_2020_190417N346","volume":"67","author":"YF Li","year":"2020","unstructured":"Li, Y. F. et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma 67, 430\u2013437 (2020).","journal-title":"Neoplasma"},{"key":"1598_CR57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","volume":"27","author":"P Voabil","year":"2021","unstructured":"Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250\u20131261 (2021).","journal-title":"Nat. Med."},{"key":"1598_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100373","volume":"2","author":"SS Talwelkar","year":"2021","unstructured":"Talwelkar, S. S. et al. Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Rep. Med. 2, 100373 (2021).","journal-title":"Cell Rep. Med."},{"key":"1598_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq6830","volume":"10","author":"B Alsaed","year":"2024","unstructured":"Alsaed, B. et al. Ex vivo modeling of precision immuno-oncology responses in lung cancer. Sci. Adv. 10, eadq6830 (2024).","journal-title":"Sci. Adv."},{"key":"1598_CR60","doi-asserted-by":"publisher","unstructured":"Hutyra-Gram Otvos, R. et al. Ex vivo drug sensitivity of pleural effusion-derived cells from lung cancer and pleural mesothelioma patients is linked to clinical response. Cancers 17, https:\/\/doi.org\/10.3390\/cancers17142363 (2025).","DOI":"10.3390\/cancers17142363"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01598-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:22:59Z","timestamp":1793661779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01598-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01598-5","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no Competing Non-Financial interest. The following Competing Financial interest was declared: S.Dursun received representation\/speaker fee from Novartis. No other competing financial interests have been declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"417"}}